This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Apolipoprotein A-1 (APOA1)	<p>Mouse studies suggest APOA1 could help treat solid tumors. In mouse models for melanoma and lung cancer, expression of human <i>APOA1</i> resulted in formation of smaller primary and metastatic tumors than no <i>Apoa1</i> expression. In wild-type mice with murine or human melanomas, APOA1 decreased tumor burden and increased survival compared with vehicle. Next steps could include testing APOA1 in mouse xenograft models for other cancers. Cerenis Therapeutics S.A.'s CER-522, a high-density lipoprotein mimetic based on a peptide analog of APOA1, is in Phase I testing to treat restenosis.</p> <p>SciBX 6(24); doi:10.1038/scibx.2013.593 Published online June 20, 2013</p>	Patented by the Cleveland Clinic; licensing status unavailable	<p>Zamanian-Daryoush, M. <i>et al. J. Biol. Chem.</i>; published online May 17, 2013; doi:10.1074/jbc.M113.468967 Contact: Stanley L. Hazen, Cleveland Clinic, Cleveland, Ohio e-mail: hazens@ccf.org</p>